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Abstract
We analyzed for associations between a variable number of tandem repeat (VNTR) poly-
morphism in the Family with sequence similarity 46, member A (FAM46A) gene and a single
nucleotide polymorphism (rs3117582) in the BCL2-Associated Athanogene 6 (BAG6) with
non small cell lung cancer in Croatian and Norwegian subjects. A total of 503 (262 Croatian
and 241Norwegian) non small cell lung cancer patients and 897 controls (568 Croatian and
329 Norwegian) were analyzed. We found that the frequency of allele b (three VNTR re-
peats) of FAM46A gene was significantly increased in the patients compared to the healthy
controls in the Croatian and the combined Croatian and Norwegian subjects. Genotype fre-
quencies of cd (four and five VNTR repeats) and cc (four VNTR repeats homozygote) of the
FAM46A gene were significantly decreased in the patients compared to the healthy controls
in the Croatian and Norwegian subjects, respectively. Logistic regression analyses re-
vealed FAM46A genotype cc to be an independent predictive factor for non small cell lung
cancer risk in the Norwegian subjects after adjustment for age, gender and smoking status.
This is the first study to suggest an association between the FAM46A gene VNTR polymor-
phisms and non small cell lung cancer. We found also that BAG6 rs3117582 SNP was as-
sociated with non small cell lung cancer in the Norwegian subjects and the combined
Croatian-Norwegian subjects corroborating the earlier finding that BAG6 rs3117582 SNP
was associated with lung cancer in Europeans. Logistic regression analyses revealed that
genotypes and alleles of BAG6 were independent predictive factor for non small cell lung
cancer risk in the Norwegian and combined Croatian-Norwegian subjects, after adjustment
for age and gender.
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Introduction
Lung cancer is the most predominant cause of cancer death globally [1]. Through epidemiolog-
ical studies many environmental risk factors have been established for lung cancer including
smoking, air pollution and industrial substances [2]. Although tobacco smoking is the major
risk factor, genetic factors also affect lung cancer susceptibility [3–5]. Direct evidence for genet-
ic predisposition to lung cancer is highlighted by several genome wide association studies
(GWAS) that has been done [6–11].
Most of the genetic association reports studying lung cancer use single nucleotide polymor-
phisms (SNPs) as markers. A genomic variant that is understudied is the variable number of
tandem repeats (VNTR) probably due to VNTR complexity and the challenges in assaying
them. These limitations do not favor the discovery of novel VNTRs as potential predictive and
prognostic factors in lung cancer etiology. Predictive and prognostic factors are important in
the diagnosis and treatment of lung cancer [12–14]. The positive long term economic impact
of robustly testing for predictive factors cannot be underestimated. This enhances the quality
of medical care by significantly reducing false positives or negatives that may impact negatively
on the treatment outcome. For example, robust testing for epidermal growth factor receptor
(EGFR) gene mutational status in non small cell lung cancer (NSCLC) patients has defined this
gene as an important predictive and prognostic factor in NSCLC diagnosis and treatment. This
has also allowed for the therapeutic targeting of this genetic locus in NSCLC treatment [15;16].
VNTRs can modulate many biological processes such as gene transcription and protein
function. They may also be responsible for many disorders in humans that include unstable
(genetic) repeat expansions [17;18]. There are few reports on the association between VNTRs
and lung cancer susceptibility in case-control studies. These include VNTRs in theH-ras gene
[19;20], interleukin-1 receptor antagonist gene (IL1RN 2) [21;22] and Mitogen-activated pro-
tein kinase 2 gene (MAPKAPK2) [23].
The Family-with-sequence-similarity 46, member A (FAM46A) gene [24] is located at chro-
mosome 6.14.1. It harbors a VNTR within its coding sequence in exon 2. This VNTR may vary
from two to seven repeats per chromosome [25;26]. The FAM46A polypeptide chain also con-
tains the Domain of unknown function 1693 (DUF1693) [27] and as such no biological role
has been assigned to the FAM46A gene as of date [28;29]. FAM46A protein interacts with the
BCL2-Associated Athanogene 6 (BAG6) protein [28] which has been reported to modify risk of
lung cancer [30]. The BAG6 gene is located on chromosome 6p21.3 and regulated apoptosis
and HSP70 [31]. FAM46A protein also interacts with the zinc finger, FYVE domain-containing
9 (ZFYVE9) protein [28] which is involved in TGF-β signaling.
We previously reported that the mouse homologue of the Fam46a gene is expressed in de-
veloping tooth buds. Due to its nuclear localization and interaction with the human transcrip-
tion factor, ZFYVE9 protein, we suggested that the FAM46A protein might be involved in
cellular proliferation [32]. In addition, we have recently reported that the FAM46A gene VNTR
is associated with increased risk of tuberculosis and osteoarthritis [33;34]. Data suggest that pa-
tients with tuberculosis are associated with increased lung cancer [35]. Based on these facts, we
hypothesized that the FAM46A gene may be involved in lung cancer and that this involvement
may be through variations in the length of the FAM46A VNTR. In addition, we analyzed for
the association of a BAG6 SNP to validate its previous reported association with lung cancer
[30]. The associations were investigated in two different European populations.
FAM46A VNTR, BAG6 rs3117582 SNP and NSCLCRisk
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Materials and Methods
Ethics Statement
The study was approved by the Medical ethics committees of the University Hospital, Universi-
ty of Rijeka, Croatia, and Regional Committees for Medical and Health Research Ethics, Oslo,
Norway. Written consents were obtained from all participants.
Subjects
The number of participants, sex and age distribution of the subjects are described in Table 1
for the both the Croatian and Norwegian subjects, respectively. Blood samples were collected
at the Clinical Institute for Transfusion Medicine, University Hospital Center Rijeka, Rijeka,
Croatia for the Croatian subjects and at National Institute of Occupational Health, Oslo, Nor-
way for the Norwegian subjects. Ethnicity of participants was established by patient or healthy
individual interview and by consulting the admission documentation at the hospitals. Some
clinical information for particularly subjects was lacking and as such, not all subjects were in-
cluded in the characteristics estimations in Table 1. Subjects were not matched for possible
confounding factors such as age, gender, and smoking status. Not all patients and controls
were typed for the two markers due to lack of particular samples.
Genomic DNA extraction
Genomic DNA from NSCLC patients and healthy controls was extracted from whole blood as
described previously [36–38]. In brief, 200 μl of whole blood was mixed with 400 μl of sucrose
buffer (0.32 M sucrose, 10 mMTris–HCl, pH 7.5, 5 mMMgCl2, 1%, v/v, Triton X-100) and in-
cubated for 1 min at room temperature. To collect white cell nuclei, samples were centrifuged
2 min at 5,000g. Precipitated nuclei were washed twice with 800 μl of sucrose buffer and centri-
fuged (2 min at 5,000g). After the second wash, the nuclei were re-suspended in 400 μl DNAzol
(Invitrogen Corporation, Carlsbad, CA, USA) and incubated at room temperature for 5 min. Ge-
nomic DNA was precipitated with 200 μl of 100% ethanol and collected by centrifugation (2 min
at 5,000g). The precipitate was washed with 1 ml of 75% ethanol and centrifuged for 1 min at
5,000g, twice. Genomic DNA was re-suspended in Tris-EDTA buffer solution (10 mM Tris-
HCl, 1 mM disodium EDTA, pH 8.0; Sigma-Aldrich Chemie Gmbh, Munich, Germany).
Genotyping by DNA-sequencing Capillary Electrophoresis
DNA fragments of 647 base pairs (bp) in length encoding the FAM46A gene were amplified
from human genomic DNA by using a FAM-labeled forward primer, designated Gfam_VF (50-
AGGGTACTTCGCCATGTCTG-30), in combination with an unlabeled reverse primer, desig-
nated GEX_R (50-CTCGTGATGGCCACAGATT-30), by PCR as previously described [33;34].
The 25 μL total volume PCR mixtures contained the following: 25 ng of genomic DNA, 0.2 μm
each of the specific primers, and 1x Paq5000 Hotstart PCR master mix (Agilent Technologies,
Inc., CA, USA). PCR was performed in a Peltier Thermal cycler (MJ Research, Massachusetts,
USA). The Paq5000 polymerase was activated by an initial step at 95°C lasting 2 min, followed
by 35 cycles of denaturing, annealing, and extension steps at 95°C for 20 s, 65°C for 20 s, and
72°C for 30 s, respectively, followed by a final extension step at 72°C for 5 min. Amplicons
were resolved by 1% ethidium bromide-stained agarose gel electrophoresis and visualized by
the Geldoc imaging system (Bio-Rad, Hercules, CA, USA). Amplicons (0.5 μl) were mixed with
0.5 μl GeneScan 1200 LIZ Size Standard (Life Technologies, NY, USA) and loaded onto a 3730
DNA Analyzer (Life Technologies, NY, USA) for allele separation. Separated alleles were ana-
lyzed by the Genemapper software (Life Technologies, NY, USA). Allele (VNTR) identity was
FAM46A VNTR, BAG6 rs3117582 SNP and NSCLCRisk
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Table 1. Characteristics of non small cell lung cancer (NSCLC) patients and normal (healthy) controls.
Subjects Characteristic Patients Controls p-value
Croatians na 215 471
Average age (males and females) 66.12 (±10.39) 42.83 (± 10.84) <0.0001
Age range (males and females) 31–92 19–73
nf 57 189
Average age (females) 66.93 (±10.99) 45.12 (±10.99) <0.0001
Age range (females) 47–85 21–68
nm 158 282
Average age (males) 65.82 (±10.18) 41 (±11.55) <0.0001
Age range (males) 31–92 19–73
Smoking status never: 37 never: na
ever: 225 ever: na
Histology Adenocarcinoma: 67
Squamous carcinoma: 113
Large cell carcinoma: 3
undetermined NSCLC: 79
Norwegians na 238 292
Average age (males and females) 64.24 (±10.22) 59.66 (±10.34) <0.0001
Age range (males and females) 25–82 40–88
nf 70 69
Average age (females) 64.04 (±10.42) 61.63 (±10.98) 0.19
Age range (females) 36–81 40–83
nm 177 223
Average age (males) 64.45 (±10.16) 59.06 (±10.08) <0.0001
Age range (males) 25–71 40–88
Smoking status never: 17 never: 0 <0.0001
ever: 229 ever: 292
Histology Adenocarcinoma: 148
Squamous carcinoma: 98
Large cell carcinoma: 34
Pooled Croatians and Norwegians na 453 760
Average age (males and females) 65.13 (±10.16) 49.29 (±10.16) <0.0001
Age range (males and females) 31–92 19–88
nf 124 258
Average age (females) 65.16 (±10.16) 49.53 (±10.16) <0.0001
Age range (females) 36–85 21–83
nm 329 502
Average age (males) 65.12 (±10.19) 49.17 (±14.07) <0.0001
Age range (males) 25–92 19–88
Smoking status never: 54 never: na
ever: 454 ever: na
Histology Adenocarcinoma: 215
Squamous carcinoma:211
Large cell carcinoma: 37
undetermined NSCLS: 79
na, male and female subjects;
nf, females subjects;
nm, males subjects;
na, not available.
doi:10.1371/journal.pone.0122651.t001
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confirmed by sequencing directly PCR amplicons from samples that were genotyped as various
homozygotes (two each). To further confirm the genotyping results, 10% of the samples were
re-genotyped with 100% concordance. Also, randomly selected samples that were genotyped as
heterozygotes were sub-cloned into TOPO Zero Blunt Sequencing plasmids (Life Technologies,
NY, USA) prior to sequencing. Sequencing reaction was performed using the BigDye chemistry
3.1 (Life Technologies, NY, USA) with forward and reverse primers GVF (50-AGGG-
TACTTCGCCATGTCTG-30) and GEX_R (50-CTCGTGATGGCCACAGATT-30), respective-
ly and resolved by the ABI 3730 DNA analyzer (Life Technologies, NY, USA).
Genotyping of BAG6 rs3117582 Single Nucleotide Polymorphism (SNP)
BCL2-Associated Athanogene 6 (BAG6) gene rs3117582 SNP was assessed by probe-based
real-time PCR assays as described by the Kits manufacturer (Life Technologies, NY, USA) in
our NSCLC patient and control groups, respectively. Stratagene MX3005 real-time PCR cycler
was applied (Agilent Technologies, Santa Clara, CA, USA) for temperature cycling and
signal quantification.
Statistical analysis
The differences in the distribution of categorical variables, including demographic characteris-
tics, selected variables, allelic and genotypic frequencies were analyzed by the chi-square (Fish-
er two tailed) method using the 2-way Contingency Table Analysis (available at http://
statpages.org/ctab2x2.html and http://research.microsoft.com/en-us/um/redmond/projects/
mscompbio/fisherexacttest/) or t-test (http://www.graphpad.com/quickcalcs/ttest1/?Format=
SD) between patients and controls. The Hardy-Weinberg analysis was done using the Arlequin
software version 3.5 (Genetics and Biometry Laboratory, University of Geneva, Geneva, Swit-
zerland), which showed that the FAM46A VNTRs and the BAG6 genotypes were in Hardy-
Weinberg equilibrium (HWE). A statistically significant difference was defined when p was
0.05. The associations between the FAM46A VNTRs and BAG6 rs3117582 SNP polymor-
phisms and non small cell lung cancer risk were estimated by computing the odds ratios (ORs)
and their 95% confidence intervals (CIs). We performed logistic regression analysis to evaluate
the influence of age, gender and smoking status as confounders for the association of FAM46A
VNTRs and BAG6 rs3117582SNP, respectively, with non small cell lung cancers in the Croa-
tian and Norwegian subjects. Smoking status could not be included as a cofounder when we
analyzed for the association of these genetic elements with non small cell lung cancer in the
Croatian subjects and the combined Croatian-Norwegian subjects because information on the
smoking status of the Croatian healthy control group was not available. Logistic regression
analyses were carried out using SPSS (version 21; SPSS Inc., Chicago, IL, USA) and a p-value
of 0.05 was set as the criterion for statistical significance.
Results
Allelic and genotypic frequencies of the FAM46A gene VNTR
The frequency of VNTR genotypes and alleles for the FAM46A gene in the patients and healthy
controls are listed in Table 2 and 3. We found twenty genotypes comprising of six alleles for
the FAM46A gene with different frequencies in the two populations. Therefore, in further anal-
yses of genotypes we chose to analyze results separately for each population, in addition to per-
forming combined analyses. Analysis of the allelic frequencies, however, showed that the
VNTR with 5 repeats (d allele in Table 3) was the most frequent allele with a similar frequency
in healthy controls in both the Croatian (42%) and Norwegian (40%) populations. We chose,
FAM46A VNTR, BAG6 rs3117582 SNP and NSCLCRisk
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therefore, d allele as the reference allele in further analysis of the odds ratios. Tables 4 and 5
show the risk for lung cancer associated with each genotype (Table 4) or allele (Table 5) com-
paring frequencies of each genotype or allele in cases and controls with the most frequent geno-
type or allele as reference. In the Croatian subjects the cd genotype and in the Norwegian
Table 2. Genotypes frequencies of FAM46A VNTR polymorphisms in Croatian and Norwegian subjects with NSCLC and healthy controls.
Subjects Variant Genotype frequency
Croatians Genotype VNTR Patients (n = 262) frequency (N) Controls (n = 568) frequency (N)
Bb 3/3 24 (0.09) 36 (0.06)
Cc 4/4 19 (0.07) 31 (0.05)
dd 5/5 40 (0.15) 92 (0.16)
ee 6/6 2 (0.01) 3 (0.01)
ff 7/7 0 1 (0.00)
ab 2/3 0 4 (0.01)
ac 2/4 0 1 (0.00)
ad 2/5 4 (0.02) 4 (0.01)
ae 2/6 0 2 (0.00)
af 2/7 0 1 (0.00)
bc 3/4 38 (0.15) 63 (0.11)
bd 3/5 69 (0.26) 135 (0.24)
be 3/6 9 (0.03) 20 (0.04)
bf 3/7 1 (0.00) 5 (0.01)
cd 4/5 34 (0.13) 111 (0.20)
ce 4/6 9 (0.03) 16 (0.03)
cf 4/7 1 (0.00) 0
de 5/6 12 (0.05) 39 (0.07)
df 5/7 0 4 (0.01)
ef 6/7 0 1 (0.00)
Norwegians Genotype VNTR Patients (n = 241) frequency (N) Controls (n = 329) frequency (N)
bb 3/3 15 (0.06) 21 (0.06)
cc 4/4 9 (0.04) 36 (0.12)
dd 5/5 50 (0.21) 64 (0.20)
ee 6/6 0 2 (0.01)
ab 2/3 1 (0.001) 2 (0.01)
ac 2/4 0 2 (0.01)
ad 2/5 1 (0.001) 4 (0.01)
ae 2/6 0 2 (0.01)
bc 3/4 37 (0.15) 40 (0.12)
bd 3/5 44 (0.18) 50 (0.15)
be 3/6 12 (0.05) 10 (0.03)
cd 4/5 47 (0.20) 56 (0.17)
ce 4/6 7 (0.03) 11 (0.03)
cf 4/7 1 (0.00) 1 (0.00)
de 5/6 15 (0.62) 27 (0.08)
df 5/7 1 (0.004) 1 (0.003)
ef 6/7 1 (0.004)
N: frequency of genotypes/alleles per group, n: total number of alleles per group.
doi:10.1371/journal.pone.0122651.t002
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subjects the cc genotype was associated with a reduced risk of lung cancer, whereas combining
both groups only cc genotype had a significant effect on reduction of the cancer risk (Table 4).
Regarding allele frequencies, only subjects with a b allele in the Croatian population had a sig-
nificant increased risk of lung cancer (Table 5).
Genotypic and Allelic frequencies of BAG6 rs3117582 SNP
For the BAG6 rs3117582 polymorphism we found a gene-dosage increased risk for lung cancer
associated with the C allele of BAG6 rs3117582 SNP in the Norwegian subjects. The subjects
carrying one C allele had 1.70-fold increased lung cancer risk and subjects with two variant al-
leles (CC) had almost 7-fold increased risk of lung cancer. No such association was present in
the Croatian subjects; however, combining the subjects from both populations the associations
remained significant and similar to the associations found in the Norwegian population
(Table 6).
Discussion
The present study investigates the association between a VNTR in exon 2 of the FAM46A gene
and a SNP (rs3117582) in the BAG6 gene and risk of NSCLC in two case-control studies from
Croatia and Norway. We found that an allele of FAM46A gene that carries three VNTR repeats
(designated as allele b) was associated with increased risk of lung cancer in the Croatian sub-
jects. In addition, a genotype of FAM46A gene with 4 and 5 VNTR repeats (designated cd) was
associated with reduced risk of cancer in these subjects. However, another genotype (cc)
Table 3. Alleles frequencies of FAM46A VNTR polymorphisms in Croatian and Norwegian subjects with NSCLC and healthy controls.
Subjects Variant Allele frequency
Croatians Allele VNTR Patients (n = 524) frequency (N) Controls (n = 1136) frequency (N)
a 2 4 (0.01) 11 (0.01)
b 3 165 (0.31) 299 (0.26)
c 4 120 (0.23) 253 (0.22)
d 4 199 (0.38) 477 (0.42)
e 6 34 (0.06) 84 (0.07)
f 7 2 (0.004) 12 (0.01)
Norwegians Allele VNTR Patients (n = 482) frequency (N) Controls (n = 658) frequency (N)
a 2 2 (0.004) 10 (0.02)
b 3 124 (0.26) 144 (0.22)
c 4 110 (0.23) 182 (0.28)
d 4 208 (0.43) 266 (0.40)
e 6 35 (0.07) 54 (0.08)
f 7 3 (0.006) 2 (0.003)
Combined Croatians and Norwegians Allele VNTR Patients (n = 1006) frequency (N) Controls (n = 1794) frequency (N)
a 2 6 (0.01) 21 (0.01)
b 3 289 (0.29) 443 (0.25)
c 4 230 (0.23) 435 (0.24)
d 4 407 (0.40) 743 (0.41)
e 6 69 (0.07) 138 (0.08)
f 7 5 (0.005) 14 (0.01)
N: frequency of genotypes/alleles per group, n: total number of alleles per group
doi:10.1371/journal.pone.0122651.t003
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conferred reduced risk to lung cancer in the Norwegian subjects. To date, this is the first report
of an association between the FAM46A gene and NSCLC
Of particular interest is our observation that the cc and cd genotypes of the FAM46A gene
confer reduced risk to NSCLC in the Norwegian and Croatian subjects, respectively. In addi-
tion, we found that the FAM46A bd and dd genotypes were the dominant genotypes in the
Croatian and Norwegian subjects, respectively. These findings may suggest that the frequency
of the dominant genotype of the FAM46A gene may influence the particular genotypes(s) that
Table 4. Association of FAM46A VNTR genotypes with NSCLC in Croatian and Norwegian subjects.
Subjects VNTR Variant Unadjusted for covariates Adjusted for covariates
Croatians Genotype OR(crude), 95% CI, pU N = 830 OR(adjusted), 95% CI, pg, N = 734
bd Reference
bb 1.03, 0.72–2.34, 0.38 1.26, 0.66–2.40, 0.48
bc 1.18, 0.72–1.94, 0.51 1.09, 0.64–1.87, 0.76
be 0.88, 0.38–2.04, 0.77 0.67, 0.24–1.93, 0.46
cc 1.20, 0.63–2.28, 0.58 1.44, 0.72–2.86, 0.31
cd 0.60, 0.37–0.97, 0.037 0.56, 0.33–0.96, 0.035
ce 1.10, 0.43–2.62, 0.83 1.23, 0.49–3.12, 0.66
dd 0.60, 0.30–1.22, 0.16 0.82, 0.5–1.37, 0.45
de 0.80 0.51–1.25, 0.33 0.54, 2.5–1.21, 0.13
LFG 0.51, 5.75E-06 0.55, 0.21–1.43, 0.22
Norwegians Genotype OR(crude), 95% CI, pU, N = 541 OR(adjusted), (95% CI), pags, N = 538
dd Reference
bb 0.92, 0.42–1.99, 0.82 0.98, 0.44–2.18. 0.96
bc 1.30, 0.71–2.34, 0.39 1.16, 0.62–2.18, 0.65
bd 1.09, 0.62–1.9, 0.77 0.97, 0.54–1.74, 0.92
be 1.39, 0.55–3.50, 0.48 1.29, 0.48–3.46, 0.62
cc 0.37, 0.16–0.86, 0.02 0.27, 0.11–0.69, 0.006
cd 1.11, 0.64–1.93, 0.70 1.05, 0.59–1.88, 0.86
ce 0.81, 0.28–2.29, 0.69 0.77, 0.27–2.22, 0.63
de 0.73, 0.34–1.53, 0.40 0.73, 0.33–1.59, 0.43
LFG 1.08, 0.46–2.51. 0.86 1.14, 0.47–2.75, 0.78
Combined Croatians and Norwegians Genotype OR(crude), 95% CI, pU, N = 1371 OR(adjusted), 95% CI), pag, N = 1222
bd+dd Reference
bb 1.16, 0.74–1.81, 0.51 1.27, 0.71–2.26, 0.43
bc 1.28, 0.91–1.81, 0.17 1.25, 0.80–1.94, 0.33
be 1.15, 0.64–2.05, 0.65 1.21, 0.55–2.67, 0.63
cc 0.78, 0.48–1.26, 0.30 0.55, 0.30–0.996, 0.048
cd 0.53, 0.60–1.14, 0.25 0.90, 0.60–1.35, 0.61
ce 1.01, 0.53–1.92, 0.98 0.97, 0.43–2.14, 0.91
de 0.70, 0.43–1.14, 0.15 0.68, 0.37–1.22, 0.19
LFG 0.88, 0.50–1.54. 0.66 1.05, 0.52–2.12, 0.90
pU: unadjusted p-value,
pg: p-value adjusted for gender,
pag: p-value adjusted for age and gender,
pags: p-value adjusted for age, gender and smoking status,
N: number of alleles or genotypes include in the analysis, LFG: Low frequency genotypes (ab+ac+ad+ae+bf+cf+af+ee+ef+ff), CI: conﬁdence interval, OR:
Odds ratio
doi:10.1371/journal.pone.0122651.t004
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associates with NSCLC risk in each population. There is the possibility that these polymor-
phisms could be markers for susceptibility or reduced risk factor for example binding sites for
Table 5. Association of FAM46A VNTR alleles with NSCLC in Croatian and Norwegian subjects.
Subjects VNTR Variant Unadjusted for
covariates
Adjusted for
covariates
Croatians Allele OR(crude),
95% CI, pU,
N = 1660
OR(adjusted),
95% CI, pg,
N = 1468
d Reference
a 0.87, 0.27–
2.77, 0.82
0.85, 0.23–
3.15, 0.81
b 1.32, 1.03–
1.70, 0.03
1.32, 1.003–
1.74, 0.048
c 1.14, 0.87–
1.49, 0.36
1.18, 0.88–
1.59, 0.27
e 0.97, 0.63–
1.49, 0.89
0.89, 0.54–
1.46, 0.64
f 0.40, 0.09–
1.80, 0.23
0.44, 0.10–
2.02, 0.29
Norwegians Allele OR(crude),
95% CI, pU,
N = 1162
OR, 95% CI,
pags, N = 1075
d Reference
a 0.25, 0.06–
1.17, 0.08
0.32, 0.07–
1.52, 0.15
b 1.09, 0.81–
1.47, 0.58
1.07, 0.78–
1.48, 0.68
c 0.76, 0.56–
1.02, 0.07
0.75,0.54–1.04,
0.08
e 0.82, 0.52–
1.30, 0.40
0.80, 0.49–
1.31, 0.37
f 1.90, 0.31–
11.44, 0.49
1.89, 0.31–
11.76, 0.49
Combined
Croatians and
Norwegians
Allele OR(crude),
95% CI, pU,
N = 2800
OR(adjusted),
95% CI, pag,
N = 2444
d Reference
a 0.52, 0.21–
1.30, 0.16
0.53, 0.17–
1.68, 0.28
b 1.19, 0.98–
1.44, 0.07
1.20, 0.94–
1.53, 0.15
c 0.97, 0.79–
1.18, 0.76
0.91, 0.71–
1.18, 0.49
e 0.90), 0.66–
1.23, 0.51
0.84, 0.56–
1.25, 0.39
f 0.65, 0.23–
1.82, 0.42
1.21, 0.35–
4.15, 0.76
pU: unadjusted p-value,
pg: p-value adjusted for gender,
pag: p-value adjusted for age and gender,
pags: p-value adjusted for age, gender and smoking status,
N: number of alleles or genotypes include in the analysis, CI: conﬁdence interval, OR: Odds ratio.
doi:10.1371/journal.pone.0122651.t005
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miRNA, CpG methylation changes, SNPs in vicinity or genetic instability. Our results may
therefore encourage further studies aimed at replicating our results, validating and/or eliminat-
ing the possibility of false positives or negatives that may be present in our results as a conse-
quence of these genetic events.
The function of the FAM46A gene and its component domains (PS50315 and DUF1693) is
unknown [25]. The DUF domain is present in many hypothetical proteins including nematode
prion-like proteins [27] and in nucleotidyltransferase superfamily genes with unknown func-
tion [27]. Our results suggest that the VNTR-encoded PS50315 domain of the FAM46A protein
might have functional importance in NSCLC. The FAM46A gene might have a role in TGF-β
signaling, cell death (apoptosis) and/or inflammation due to its interaction with the ZFYVE9
protein [28]. An experimentally determined interacting partner of the FAM46A protein is the
Table 6. Association of BAG6 SNP 3117582 with NSCLC in Croatian and Norwegian subjects.
Subjects SNP
Variant
Number of cases
(n)
Number of healthy
controls (n)
Unadjusted for
covariates
Adjusted for
covariates
Croatians Genotype n = 262 n = 568 OR(crude), 95% CI, pU OR(adjusted), 95% CI,
pag
AA 218 491 Reference
AC 41 69 1.34, 0.88–2.03, 0.17 1.46, 0.94–2.29, 0.095
CC 2 4 1.13, 0.21–6.19, 0.89 1.59, 0.26–6.67, 0.61
Norwegians Genotype n = 249 n = 332 OR(crude), 95% CI, pU OR(adjusted), 95% CI,
pags
AA 170 271 Reference
AC 62 58 1.70, 1.16–2.56, 0.01 1.68, 1.08–2.61, 0.02
CC 8 3 4.25, 1.11–16–25, 0.03 7.06, 1.45–34.40, 0.016
Combined Croatians and
Norwegians
Genotype n = 498 n = 664 OR(crude), 95% CI, pU OR (adjusted), 95% CI,
pag
AA 340 542 Reference
AC 124 116 1.70, 1.28–2.27, 0.0003 1.72, 1.27–2.33, 0.0005
CC 16 6 4.25, 1.65–10.97, 0.003 6.89, 2.24–21.14,
0.0007
Croatians Allele n = 522 n = 1128 OR(crude), 95% CI, pU OR(adjusted), 95% CI,
pag
a 475 1050 Reference
c 47 78 1.33, 0.91–1.94, 0.14 1.48, 0.99–2.22, 0.056
Norwegians Allele 498 n = 664 OR(crude), 95% CI, pU OR(adjusted), 95% CI,
pags
a 340 542 Reference
c 140 122 1.83, 1.39–2.42,
0.00002
1.88, 1.39–2.54,
0.00004
Combined Croatians and
Norwegians
Allele n = 1022 n = 1800 OR(crude), 95% CI, pU OR(adjusted), 95% CI,
pag
a 815 1529 Reference
c 187 200 1.83, 1.47–2,67,
4.96x10-8
1.63, 1.24–2.13, 0.0004
pU: unadjusted p-value,
pg: p-value adjusted for gender,
pag: p-value adjusted for age and gender,
pags: p-value adjusted for age, gender and smoking status,
N: number of alleles or genotypes include in the analysis, n: numbers of alleles or genotypes, CI: conﬁdence interval, OR: Odds ratio.
doi:10.1371/journal.pone.0122651.t006
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ZFYVE9 protein [28]. ZFYVE9 protein is involved in the recruitment of unphosphorylated
forms of SMAD2/SMAD3 to the TGF-β receptor (TGF-βR) [39]. Phosphorylation of SMAD2/
SMAD3 induces dissociation from ZFYVE9. This allows for the formation of SMAD2/SMAD4
complexes and the consequent translocation of the SMAD2/SMAD4 complexes to the nucleus.
Perhaps the FAM46A protein is involved in this cascade of events. TGF-β is a potent inhibitor
of cell growth and accumulating evidence suggests that perturbation of TGF-β signaling path-
way leads to tumorigenesis [40]. It is therefore tempting to speculate that FAM46A protein
may be involved in lung cancer etiology through its participation in the TGF-β signaling path-
way. This may involve the VNTR-encoded PS50315 domain of FAM46A gene. Our results may
therefore encourage further studies to validate this postulation.
We found that the BAG6 rs3117582 SNP is associated with NSCLC both at the genotypic
and allelic levels in the Norwegian subjects and the combined Croatian and Norwegian sub-
jects. This is interesting since BAG6 protein is an interacting partner of FAM46A protein [28].
Previous reports have shown that SNPs in BAG6 gene (rs1052486 and rs3117582) conferred
susceptibility to lung cancer [8;30]. Our results support these previous reports and further sug-
gest a role for the BAG6 gene in the etiology of non small cell lung cancer. BAG6 polypeptides
regulates a variety of cellular processes such as apoptosis [41], HLA class II expression [42], T
cell responses [43], protein modification and gene expression [44]. All these processes may re-
quire that the BAG6 protein is constitutively expressed at steady-state levels for optimal func-
tioning. In addition, the BAG6 rs3117582 SNP is located at the promoter region of the BAG6
gene (38 basepairs from the transcription start site). Mutations at the promoter region of genes
have been shown to influence the expression levels of the respective genes. This may concur-
rently attenuate the physiological efficiency of the genes in a dose-response manner [45;46].
Our results suggest that the C allele of BAG6 rs3117582 SNP is associated with increased risk
for NSCLC in the Norwegian subjects and the combined Croatian and Norwegian subjects in a
gene-dosage manner. This may also suggest that, the presence of the minor C allele of BAG6
rs3117582 SNP in its promoter may perturbed the BAG6 gene expression. This perturbation
may lead to significant increase in NSCLC risk in individuals that bear this allele. This postula-
tion needs to be investigated in further studies to determine and ascertain the possible underly-
ing mechanism(s) of action.
In conclusion, our study suggests that the FAM46A gene VNTR and BAG6 rs3117582 SNP
are associated with NSCLC in both the Croatian and Norwegian populations. Our results also
corroborate the previous findings that BAG6 gene is associated with lung cancer and suggest
gene-dosage association of the BAG rs3117582 SNP with NSCLC. We further suggest that
these loci could be potential research targets that might have therapeutic potentials.
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